5 / 1023
ESTRO 35 content
Saturday 30 April 2016
Teaching Lecture
Technology assessment (Abs. 1)
CRISPR/CAS technology: from cells to mice to stem cell therapy (Abs. 2)
Partial Breast Irradiation: who, when and how? (Abs. 3)
New tools to reduce toxicity in pelvic radiation (Abs. 4)
Role of brachytherapy in the management of paediatric tumors (Abs. 5)
Challenges in MR guided radiotherapy (Abs. 6)
Patient specific quality assurance in proton therapy (Abs. 7)
Balancing toxicity and disease control in the evolution of
radiotherapy technology (Abs. 8)
Symposium
Selection of patients for proton therapy (Abs. 9-11)
Mitigating normal tissue toxicity (Abs. 12-14)
Regional nodal irradiation for breast cancer (Abs. 15-17)
Assessment and management of rectal morbidity (Abs. 18-20)
Towards user oriented QA procedures for treatment verification (Abs.
21-23)
Robust and accurate functional MRI for radiotherapy (Abs. 24-26)
Joint Symposium
ESTRO-IAEA: Joint ESTRO-IAEA efforts on dosimetry, QA and audit for
advanced treatment techniques (Abs. 27-29)
Symposium
Strategies for treatment planning (Abs. 30-32)